Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

mAIcompass Multimodal AI-based Clinical prOgnostic Models for PArkinson's Symptoms progression and Subtyping

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
16 August 2027 to 15 November 2030
Status
Running
EU funding
€436k
Total cost
—
Partners
3 organisations in 3 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101277542

What the project is doing

In the project's own words, from its summary on CORDIS.

Parkinson’s Disease (PD) is the fastest-growing neurological condition with global cases estimated to double to 20M by 2050. The spectrum, onset and progression of PD symptoms are highly heterogeneous between individuals, hampering treatment personalization through early prediction of disease course. I aim to develop mAIcompass; a multimodal AI-based clinical application, that leverages longitudinal clinical and imaging data, acquired during follow-up examinations, to facilitate real-time prognostication of PD progression, in terms of motor function deterioration, cognitive decline and neuropsychiatric impairment.

It will also aid the early prediction of the overall progression subtype, based on neurobiological phenotypes of PD subgroups with similar progression pattern, identified through temporal clustering. The fellowship will be hosted by the Neuropsychiatry team of Amsterdam UMC that leads ENIGMA PD consortium, the largest existing international collection of PD datasets. I will leverage advanced expertise to develop novel algorithms for longitudinal PD data modelling and subtyping at the Center for AI and Data Science for Integrated Diagnostics, University of Pennsylvania (outgoing phase).

Upon validation of expert clinicians and engineers, I will integrate the AI models into a user-friendly standalone application software intended for educational, research and experimental clinical use. Feedback for its utility will be obtained from end-users and patients focus groups at a PD clinical center. These tasks will set a roadmap for mAIcompass future clinical implementation, that is expected to aid the personalized PD clinical management, towards maximizing patients’ treatment benefit and reducing healthcare costs, proportionally varying with PD progression. mAIcompass aspires to link its expected scientific, societal and economic impacts to the Parkinson’s Manifesto for Europe, as well as to EU priorities emphasizing promotion of citizens' health and well-being.

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Diagnostikon Kai Therapeftikon Kentron Athinon Ygeia Anonymos EtaireiaMarousiGreeceAssociatedpartner
The Trustees of the University of Pennsylvania CorpPhiladelphiaUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI